CSF2 and neoplasm: This greater in vivo antitumor effect of EHMK carrier cells might be a result of further significant induction of anti‐adenoviral CTL and anti‐tumor immunity via the combination of GM‐CSF with more antigen‐presenting ability in addition to a greater direct antitumor effect via the increased oncolytic adenovirus production and infectivity.